Evidence map›Paper›PMID 36421424›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Quercetin Ameliorates Renal Injury and Pyroptosis in Lupus Nephritis through Inhibiting IL-33/ST2 Pathway In Vitro and In Vivo.

Hsin-Yuan Chen, Yi-Fen Chiang, Yong-Han Hong, Tzong-Ming Shieh, Tsui-Chin Huang, Mohamed Ali, Hsin-Yi Chang, Kai-Lee Wang, Shih-Min Hsia

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. A comprehensive review ofFrontiers in pharmacology · 2023
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Hsin-Yuan ChenSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0002-2411-426X
Yi-Fen ChiangSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110301, Taiwan.
Yong-Han HongGraduate Programs of Nutrition Science, School of Life Science, National Taiwan Normal University, Taipei 106209, Taiwan.
Tzong-Ming ShiehSchool of Dentistry, College of Dentistry, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0003-1759-9120
Tsui-Chin HuangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-7873-132X
Mohamed AliClinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.ORCID 0000-0002-9675-6691
Hsin-Yi ChangGraduate Institute of Medical Science, National Defense Medical Center, Taipei 114, Taiwan.ORCID 0000-0002-2742-0676
Kai-Lee WangDepartment of Nursing, Ching Kuo Institute of Management and Health, Keelung 20301, Taiwan.
Shih-Min HsiaSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0003-2888-2618
Taipei Medical University · TWAin Shams University · EGChina Medical University · TWChing Kuo Institute of Management and Health · TWNational Defense Medical Center · TWNational Taiwan Normal University · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus nephritis (LN) is a common and serious symptom in patients with systemic lupus erythematosus (SLE). Tubular interstitial fibrosis is a common underlying mechanism in the development of lupus nephritis to end-stage renal failure (ESRD). Quercetin is widely proven to prevent tissue fibrosis. Therefore, the purpose of this study is to investigate the beneficial effects of quercetin on the inhibition of fibrosis and inflammation pathways in in vitro and in vivo lupus nephritis models. In the current study, MRL/lpr mice as animal models, and HK-2 human renal tubular epithelial cells were stimulated by interleukin-33 (IL-33) to mimic the cellular model of lupus nephritis. Immunohistochemical staining, immunoblotting assay, immunofluorescence staining, and quantitative real-time polymerase chain reaction assay were used. The in vivo results showed that quercetin improved the renal function and inhibited both fibrosis- and inflammation-related markers in MRL/lpr mice animal models. The in vitro results indicated that quercetin ameliorated the accumulation of fibrosis- and inflammation-related proteins in IL-33-induced HK-2 cells and improved renal cell pyroptosis via the IL33/ST2 pathway. Overall, quercetin can improve LN-related renal fibrosis and inflammation, which may offer an effective potential therapeutic strategy for lupus nephritis.

Indexed as

inflammationinterleukin-33lupus nephritisquercetinrenal fibrosissystemic lupus erythematosus

Identifiers

PMID36421424
PMCPMC9687047
OpenAlexW4308971912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.